AU2011347718B2 - N-substituted azetidine derivatives - Google Patents
N-substituted azetidine derivatives Download PDFInfo
- Publication number
- AU2011347718B2 AU2011347718B2 AU2011347718A AU2011347718A AU2011347718B2 AU 2011347718 B2 AU2011347718 B2 AU 2011347718B2 AU 2011347718 A AU2011347718 A AU 2011347718A AU 2011347718 A AU2011347718 A AU 2011347718A AU 2011347718 B2 AU2011347718 B2 AU 2011347718B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- alkyl
- cancer
- formulae
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10196960.8 | 2010-12-24 | ||
| EP10196960 | 2010-12-24 | ||
| PCT/EP2011/073041 WO2012084711A1 (en) | 2010-12-24 | 2011-12-16 | N-substituted azetidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011347718A1 AU2011347718A1 (en) | 2013-05-30 |
| AU2011347718B2 true AU2011347718B2 (en) | 2016-06-23 |
Family
ID=43778253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011347718A Ceased AU2011347718B2 (en) | 2010-12-24 | 2011-12-16 | N-substituted azetidine derivatives |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9540361B2 (enExample) |
| EP (1) | EP2655367B1 (enExample) |
| JP (1) | JP5886873B2 (enExample) |
| AU (1) | AU2011347718B2 (enExample) |
| CA (1) | CA2819299A1 (enExample) |
| ES (1) | ES2586908T3 (enExample) |
| WO (1) | WO2012084711A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| SG11201403002RA (en) | 2011-12-14 | 2014-07-30 | Seragon Pharmaceuticals Inc | Fluorinated estrogen receptor modulators and uses thereof |
| HUE039052T2 (hu) | 2013-02-19 | 2018-12-28 | Novartis Ag | Benzotiofénszármazékok és azok készítményei szelektív ösztrogén receptor lebontóként |
| CN117865872A (zh) | 2014-12-18 | 2024-04-12 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| WO2016174551A1 (en) * | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| DK3355884T3 (da) | 2015-10-01 | 2021-08-02 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler |
| CN108349952A (zh) * | 2015-11-09 | 2018-07-31 | 豪夫迈·罗氏有限公司 | 四氢萘雌激素受体调节剂及其用途 |
| ES2935125T3 (es) | 2015-12-09 | 2023-03-01 | Univ Illinois | Reguladores a la baja selectivos de los receptores de estrógenos con base en benzotiofeno |
| AU2017221083B2 (en) * | 2016-02-15 | 2021-06-24 | Sanofi | 6,7-dihydro-5H-benzo[7]annulene derivatives as estrogen receptor modulators |
| US9969732B2 (en) * | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| BR112018077136A2 (pt) | 2016-07-01 | 2019-04-30 | G1 Therapeutics, Inc. | composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis. |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| JOP20190090B1 (ar) * | 2016-10-24 | 2023-03-28 | Astrazeneca Ab | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان |
| SG11201903908PA (en) | 2016-11-17 | 2019-05-30 | Sanofi Sa | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| AR110728A1 (es) | 2017-01-06 | 2019-04-24 | G1 Therapeutics Inc | Terapia combinada para el tratamiento del cáncer |
| WO2018138739A1 (en) | 2017-01-27 | 2018-08-02 | Sun Pharma Advanced Research Company Limited | Novel antiestrogenic heterocyclic compounds |
| TW201835064A (zh) | 2017-02-10 | 2018-10-01 | 美商G1治療公司 | 苯并噻吩雌激素受體調節劑 |
| GB201706806D0 (en) | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP3641762B1 (en) | 2017-06-20 | 2026-02-18 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CA3067873A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of g1t38 and methods of manufacture thereof |
| EP3434272A1 (en) | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| WO2019157020A1 (en) | 2018-02-06 | 2019-08-15 | The Board Of Trustees Of The University Of Illinois | Substituted benzothiophene analogs as selective estrogen receptor degraders |
| TWI915239B (zh) | 2018-06-21 | 2026-02-11 | 瑞士商赫孚孟拉羅股份公司 | 3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法 |
| ES2923412T3 (es) | 2018-09-07 | 2022-09-27 | Sanofi Sa | Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| CA3144791A1 (en) | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| JP7680438B2 (ja) | 2019-10-01 | 2025-05-20 | サノフイ | 新規の置換６，７－ジヒドロ－５ｈ－ベンゾ［７］アンヌレン化合物、その製造方法およびその治療的使用 |
| BR112022009705A2 (pt) | 2019-12-09 | 2022-08-09 | Sanofi Sa | Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica |
| EP4681715A3 (en) | 2019-12-20 | 2026-01-28 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| IL295709A (en) | 2020-03-05 | 2022-10-01 | C4 Therapeutics Inc | Compounds for targeted degradation of brd9 |
| MX2022010425A (es) | 2020-03-06 | 2022-09-07 | Olema Pharmaceuticals Inc | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. |
| EP4192458A4 (en) | 2020-08-05 | 2024-09-04 | C4 Therapeutics, Inc. | COMPOUNDS FOR TARGETED DEGRADATION OF RET |
| US12595230B2 (en) | 2020-10-19 | 2026-04-07 | Sanofi | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| AU2021366223A1 (en) | 2020-10-19 | 2023-06-22 | Sanofi | Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| CN113248455A (zh) * | 2021-05-25 | 2021-08-13 | 湖北科技学院 | 一种3,5-二取代异噁唑类衍生物及其合成方法 |
| JP2024523839A (ja) | 2021-06-08 | 2024-07-02 | シーフォー セラピューティクス， インコーポレイテッド | 突然変異体ｂｒａｆを分解する療法薬 |
| WO2023059714A1 (en) * | 2021-10-06 | 2023-04-13 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| KR20250055538A (ko) | 2022-08-03 | 2025-04-24 | 브리스톨-마이어스 스큅 컴퍼니 | Ret 단백질을 조정하기 위한 화합물 |
| CN117924262A (zh) * | 2022-10-14 | 2024-04-26 | 中国科学院上海药物研究所 | 二氢苯并噻喃类衍生物及其制备方法和用途 |
| JP2025540906A (ja) | 2022-11-04 | 2025-12-17 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｅｔ－ｌｄｄタンパク質阻害剤 |
| CN120569388A (zh) | 2022-11-04 | 2025-08-29 | 百时美施贵宝公司 | Ret-ldd蛋白降解剂 |
| CN116813603B (zh) * | 2023-06-02 | 2024-10-22 | 成都市第三人民医院 | 一种选择性雌激素受体α降解化合物及其制备方法和应用 |
| AU2024310341A1 (en) | 2023-06-30 | 2026-02-12 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1577288A1 (en) * | 2002-12-26 | 2005-09-21 | Eisai Co., Ltd. | Selective estrogen receptor modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3983245A (en) * | 1975-02-06 | 1976-09-28 | Smithkline Corporation | Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes |
| US6750213B2 (en) | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| DOP2002000467A (es) * | 2001-10-10 | 2003-04-15 | Pfizer Prod Inc | 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas |
| TW200304371A (en) * | 2002-02-22 | 2003-10-01 | Akzo Nobel Nv | Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors |
| US20030225132A1 (en) | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
| SI1501819T1 (sl) | 2002-04-24 | 2011-01-31 | Merck Sharp & Dohme | Modulatorji estrogen receptorjev |
| AU2008326381B2 (en) * | 2007-11-21 | 2014-10-23 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating inflammation |
-
2011
- 2011-12-16 US US13/995,237 patent/US9540361B2/en active Active
- 2011-12-16 ES ES11794797.8T patent/ES2586908T3/es active Active
- 2011-12-16 JP JP2013545218A patent/JP5886873B2/ja not_active Expired - Fee Related
- 2011-12-16 AU AU2011347718A patent/AU2011347718B2/en not_active Ceased
- 2011-12-16 EP EP11794797.8A patent/EP2655367B1/en active Active
- 2011-12-16 CA CA2819299A patent/CA2819299A1/en not_active Abandoned
- 2011-12-16 WO PCT/EP2011/073041 patent/WO2012084711A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1577288A1 (en) * | 2002-12-26 | 2005-09-21 | Eisai Co., Ltd. | Selective estrogen receptor modulators |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2819299A1 (en) | 2012-06-28 |
| US20160130262A1 (en) | 2016-05-12 |
| WO2012084711A1 (en) | 2012-06-28 |
| JP2014503537A (ja) | 2014-02-13 |
| JP5886873B2 (ja) | 2016-03-16 |
| ES2586908T3 (es) | 2016-10-19 |
| EP2655367B1 (en) | 2016-07-06 |
| AU2011347718A1 (en) | 2013-05-30 |
| EP2655367A1 (en) | 2013-10-30 |
| US9540361B2 (en) | 2017-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9540361B2 (en) | N-substituted azetidine derivatives | |
| BRPI0610183A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| ES2585653T3 (es) | Antagonistas del receptor de FSH | |
| AU2024236161A1 (en) | Acylsulfonamide kat6a inhibitors | |
| KR20080033277A (ko) | 헬릭스 12 유도된 비스테로이드성 항안드로겐 | |
| CN105518016B (zh) | 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物 | |
| CN1447791A (zh) | 药用的10－芳基－11H－苯并[b]芴衍生物和类似物 | |
| BRPI0713743B1 (pt) | Composto, pró-droga, e, composição farmacêutica | |
| JP2011500849A (ja) | エストロゲン受容体に対して活性を有する縮合化合物 | |
| ZA200210201B (en) | Benzofuran Derivatives. | |
| CN102791688A (zh) | 雌激素受体配体 | |
| CN111770924B (zh) | 用于治疗乳腺癌的雌激素受体降解剂 | |
| CN109265471B (zh) | Fxr受体激动剂 | |
| CA2585337C (en) | Trisubstituted thiophenes as progesterone receptor modulators | |
| JP2022537330A (ja) | インダゾール誘導体、その製造方法及び医薬上のその使用 | |
| US7071205B2 (en) | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | |
| CN111615515A (zh) | 杂环化合物、制备方法及其在医药上的应用 | |
| JP4647214B2 (ja) | エストロゲン受容体に対して選択的に作用させるための、置換１０−アリール−１１Ｈ−ベンゾ［ｂ］フルオレン及び７−アリール−５，６−ジヒドロ−ベンゾ［ａ］アントラセン | |
| US7084151B2 (en) | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds | |
| EP2459551B1 (en) | Dihydrobenzoindazoles | |
| US8071589B2 (en) | Dihydrobenzoindazoles | |
| US7163946B2 (en) | 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | |
| US20030130340A1 (en) | Novel benzothiophene derivatives | |
| GB2459133A (en) | Therapeutic 2-(4-substituted-phenyl)-3-(cyclyl containing)-5-hydroxy-benzo[b]thiophene derivatives as estrogen receptor ligands | |
| CN119948023A (zh) | 含哌啶多环类衍生物调节剂、其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |